Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
Chỉ hiển thị Multimedia
Tamoxifen interruption for pregnancy feasible in young breast cancer survivors
08 Jan 2026
bởiAudrey Abella
A real-world Asian study presented at ESMO Asia 2025 supports temporary tamoxifen interruption for young breast cancer survivors who are considering pregnancy.
Tamoxifen interruption for pregnancy feasible in young breast cancer survivors
08 Jan 2026
Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6
06 Jan 2026
bởiAudrey Abella
In the phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly improved progression-free survival (PFS) compared with tislelizumab plus chemo as first-line treatment for individuals with advanced squamous non-small cell lung cancer (NSCLC).
